Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 27 May 2020, 10:41 HKT/SGT
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences' COVID-19 Neutralizing Antibodies
- CB6 demonstrated prophylactic and treatment effects in rhesus monkeys
- Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company

SHANGHAI, CHINA, May 27, 2020 - (ACN Newswire) - Junshi Biosciences (HKEX: 1877) a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the publication of research results from the company's efforts to generate therapeutic COVID-19 neutralizing antibodies. The paper, titled "A human neutralizing MAb targeting the receptor binding site of SARS-CoV-2" (Shi et al. Nature), was published today in the journal Nature. Junshi and partner Eli Lilly and Company (NYSE: LLY) intend to file an IND and initiate clinical trials in the U.S. and China in the second quarter of 2020.

The article reports the identification and characterization of two specific human monoclonal antibodies (CA1 and CB6) isolated from a recovered COVID-19 patient. While both antibodies demonstrated substantial neutralization activity in vitro against SARS-CoV-2, CB6 exhibited superior neutralizing activities. CB6 reduced virus levels by about 3 logs in rhesus monkeys when administered one day after infection. When given one day before viral challenge, CB6 was able to keep viral load at no more than 103 RNA copies/ml, demonstrating strong prophylactic protection. Structural studies showed that CB6 recognizes epitopes in SARS-CoV-2 receptor binding domain that overlap with angiotensin converting enzyme 2 (ACE2)-binding sites, thereby directly obstructing virus/receptor interactions. The Fc portion of CB6 was modified to lower the risk of Fc mediated acute lung injury.

"We have successfully leveraged the Company's years of expertise with our fully integrated R&D antibody technology platform, conducting multiple parallel development tracks of candidate antibodies that were subsequently tested in vivo infection model by the Institute of Microbiology, Chinese Academy of Sciences," said Hui Feng, Ph.D., Junshi Biosciences' Chief Operating Officer. "One of these candidates, described in the Nature paper, demonstrated strong neutralizing activity against COVID-19. We expect to file an IND for this candidate in the second quarter in collaboration with our partner, Lilly. As part of our effort to contribute in the fight against this global pandemic, our Company has increased its research and development efforts, leveraging our strengths in the field of antibody discovery."

"Lilly is proud to have partnered with Junshi Biosciences to develop CB6 as a potential treatment for COVID-19. The fact that CB6 can protect rhesus monkeys from COVID-19 infection suggests a potential for prophylactic use in humans," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "We are moving as quickly as possible to test such a protective effect in patients at risk for COVID-19."

The paper can be accessed on the journal's website here.

About Junshi Biosciences
Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and Infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit:

Contact Information
IR Team:
[email protected]
+ 86 021-2250 0300

May 27, 2020 10:41 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
Construction Machinery Industry Displays Vibrant Growth in Mainland China, Precision Tsugami Achieves nearly 140% Growth in Construction Machinery-Related Orders  
Sept 28, 2020 19:39 HKT/SGT
Smart Cybersecurity Summit to Help Companies Build Resilience Beyond the Crisis  
Sept 28, 2020 17:14 HKT/SGT
Insumate(R)--Patented Peptide Sequence mcIRBP-19: a Boon for Diabetics Says Greenyn Biotechnology  
Sept 28, 2020 16:00 HKT/SGT
MITSUBISHI L200 Won Russia Car of the Year 2020 and Two Other Prestigious Awards  
Sept 28, 2020 14:26 HKT/SGT
Honda Exhibits World Premiere of "Honda SUV e:concept" at the 2020 Beijing International Automotive Exhibition (Auto China 2020)  
Sept 28, 2020 09:22 HKT/SGT
Hitachi ABB Power Grids Energizes First Phase of Raigarh-Pugalur 800 kV UHVDC Transmission Link  
Sept 28, 2020 08:18 HKT/SGT
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis  
Sept 28, 2020 08:04 HKT/SGT
Zijin Mining's Announcement in relation to the Environmental, Social and Governance Framework and Formulation of 8 Policy Statements  
Sept 28, 2020 07:00 HKT/SGT
CMEE 2020 Promotes Development and Cooperation in Marine Economy  
Sept 27, 2020 16:00 HKT/SGT
Nordic Cosmetics Launches Chinese Flagship CBD Store on Tmall  
Sept 26, 2020 17:00 HKT/SGT
More Press release >>
More >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: